Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Chemotherapy in Perioperative Esophageal/GEJ Cancer
NCT06198465Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in esophageal carcinoma, esophagogastric junction carcinoma, sponsored by Xijing Hospital. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
esophageal carcinomaesophagogastric junction carcinoma
Beyond the preview
Go deeper on NCT06198465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06198465.